Inovio Collaborates with Beijing Advaccine to Advance the Development of INO-4800 Vaccine Targeting Coronavirus in China

 Inovio Collaborates with Beijing Advaccine to Advance the Development of INO-4800 Vaccine Targeting Coronavirus in China

Inovio Collaborates with Beijing Advaccine to Advance the Development of INO-4800 Vaccine Targeting Coronavirus in China

Shots:

  • Inovio is currently evaluating INO-4800 vaccine in P-I study assessing its safety and immunogenicity in the US and is supported by a grant of ~$9M from the Coalition for Epidemic Preparedness Innovations (CEPI)
  • The focus of the collaboration is to deploy Advaccine’s expertise to initiate P-I study in China in parallel with its clinical study in the US. The companies will work together to attract additional funding and further collaborates with other companies to speed up the testing of INO-4800
  • The collaboration allows Inovio to enter in China and deliver its vaccine to the patients. Additionally, Inovio will initiate P-II study for INO-4700 in the Middle East against MERS viral outbreak

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image:  Smarteranalyst

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post